← All trials
NCT05718856
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 23, 2023
- Primary completion
- May 14, 2024
- Completion date
- Nov 14, 2024
- First posted
- Feb 8, 2023
- Last posted
- Oct 18, 2023
- Enrollment
- 166
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesOverall official - principal investigator
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- Kunming Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Xiamen UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Henan Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.